- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 15.04. | Transcode Therapeutics, Inc. - 10-K, Annual Report | - | SEC Filings | ||
| 07.04. | Transcode Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 03.03. | Transcode Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 23.02. | Transcode Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 05.02. | Transcode Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 05.02. | TransCode Therapeutics, Inc.: TransCode Therapeutics and Quantum Leap Announce Submission of IND Amendment for Phase 2a Clinical Trial with TTX-MC138 | 485 | PR Newswire | BOSTON, Feb. 5, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ) (TransCode), a clinical stage company pioneering immuno-oncology and RNA therapeutics... ► Artikel lesen | |
| 06.01. | Transcode Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| TRANSCODE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 22.12.25 | TransCode Therapeutics appoints Jack E. Stover to board of directors | 2 | Investing.com | ||
| 22.12.25 | Transcode Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 11.12.25 | TransCode Therapeutics, Inc.: TransCode Therapeutics and Quantum Leap Healthcare Collaborative Launch a Phase 2a dose-expansion trial with TTX-MC138, following positive readouts from TransCode's Phase 1 trial | 303 | PR Newswire | BOSTON, Dec. 11, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ) and Quantum Leap Healthcare Collaborative ("Quantum Leap") today announce a new collaboration to evaluate... ► Artikel lesen | |
| 11.12.25 | Transcode Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 14.10.25 | TransCode Therapeutics, Inc.: TransCode Therapeutics presents preliminary data from its completed Phase 1a study with TTX-MC138 in metastatic disease at ESMO | 319 | PR Newswire | Safety primary endpoint achieved
Median treatment duration of 4 months with a range of 2 to 12 months and three patients remain on trial
RECIST data with... ► Artikel lesen | |
| 08.10.25 | TransCode Therapeutics, Inc.: TransCode Therapeutics (RNAZ) announces the acquisition of Polynoma and a $25 Million strategic financing by a subsidiary of CK Life Sciences to form a first-in-class unique immuno-oncology ... | 309 | PR Newswire | TransCode acquires 100% of the issued and outstanding interests of Polynoma from CK Life Sciences
Concurrent equity investment of $25 Million from CK Life Sciences... ► Artikel lesen |
13 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 76,15 | +0,59 % | Biotech und die Effizienz-Revolution: Warum für Novartis, BioNTech und BioNxt die letzte Meile entscheidet | Während für Biotech-Investoren über Jahrzehnte hinweg das Dogma galt, dass nur die Entdeckung eines völlig neuen Moleküls den Weg zu einem Milliarden-Exit ebnen kann, zeigt die Realität des Marktes... ► Artikel lesen | |
| QIAGEN | 29,490 | +3,11 % | Qiagen erhöht Dividende und stellt weitere Aktienrückkäufe in Aussicht | DJ Qiagen erhöht Dividende und stellt weitere Aktienrückkäufe in Aussicht
DOW JONES--Die Aktionäre von Qiagen können sich über eine höhere Dividende freuen. Wie es in der Einladung zur Hauptversammlung... ► Artikel lesen | |
| NOVAVAX | 7,610 | -0,65 % | Novavax, Inc.: Novavax Reports First Quarter 2026 Financial Results and Operational Highlights | Total revenue of $140 million in the first quarter of 2026
Pfizer agreement announced in January for non-exclusive license to utilize Matrix-M® in two infectious... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 14,790 | 0,00 % | Palatin Technologies, Inc.: Palatin to Begin Trading on Nasdaq Stock Exchange | PRINCETON, N.J., May 18, 2026 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company focused on the discovery and development... ► Artikel lesen | |
| BRAIN BIOTECH | 2,950 | +2,43 % | EQS-News: BRAIN Biotech AG: BRAIN Biotech erhält bedeutendes Patent für seine CRISPR-BMC Genome-Editing-Technologie | EQS-News: BRAIN Biotech AG
/ Schlagwort(e): Patent
BRAIN Biotech erhält bedeutendes Patent für seine CRISPR-BMC Genome-Editing-Technologie
23.03.2026 / 11:05 CET/CEST
Für... ► Artikel lesen | |
| VIVOSIM LABS | 1,280 | +0,79 % | VivoSim Labs, Inc.: VivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global Sales | SAN DIEGO, March 03, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim"), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,062 | +0,95 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports First Quarter 2026 Financial Results and Recent Business Highlights | Biologics License Application (BLA) for INO-3107 actively being reviewed under the accelerated approval program by the U.S. Food and Drug Administration (FDA)... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 1,260 | -1,56 % | COSCIENS Biopharma Inc. Reports Q1 2026 Results | TORONTO, ONTARIO, May 12, 2026 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCIF) ("COSCIENS" or the "Company") today reported its financial and operating results for the first... ► Artikel lesen | |
| XOMA ROYALTY | 36,200 | +1,12 % | Ligand Pharmaceuticals und XOMA Royalty passen Fusionsvereinbarung an | ||
| MOSAIC IMMUNOENGINEERING | - | - | Mosaic ImmunoEngineering Inc. - NT 10-Q, Notification of inability to timely file Form 10-Q or 10-QSB | ||
| PHIO PHARMACEUTICALS | 1,085 | +0,46 % | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update | Key Development Agreements Secured for Nonclinical Toxicology and U.S. cGMP Clinical Supply ManufacturingKing of Prussia, Pennsylvania--(Newsfile Corp. - May 7, 2026) - Phio Pharmaceuticals Corp.... ► Artikel lesen | |
| ORAGENICS | 0,595 | 0,00 % | Oragenics reports Q1 results | ||
| VIVUS | - | - | VIVUS B.V.: VIVUS Reinforces QSIVA's Clinical Efficacy and Safety in Obesity Management | - QSIVA offers clinically meaningful weight loss supported by a well-established safety profile, now available at a reduced price across Nordics and Poland
AMSTERDAM, March 25, 2026 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| TENAX THERAPEUTICS | 9,750 | 0,00 % | TENAX THERAPEUTICS, INC. - S-8, Securities to be offered to employees in employee benefit plans | ||
| EDESA BIOTECH | 8,550 | +9,62 % | Edesa Biotech, Inc.: Edesa Biotech Reports Fiscal 2nd Quarter 2026 Results | TORONTO, May 14, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases... ► Artikel lesen |
TRANSCODE THERAPEUTICS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +5,02 % bei einem Aktienkurs von 6,480 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TRANSCODE THERAPEUTICS INC finden Sie auf Wallstreet Online.